Table 1. Patient demographics.
| Patient demographics (N=50) | |
|---|---|
| Age (years) | 62.3±12.1 |
| Gender | |
| Male (%) | 31 (62) |
| Female (%) | 19 (38) |
| Stage | |
| M1a (%) | 6 (12) |
| M1b (%) | 13 (26) |
| M1c (%) | 31 (62) |
| Prior treatment | |
| Chemotherapy (%) | 2 (4) |
| Vaccine (%) | 1 (2) |
| None (%) | 47 (94) |
| Baseline lactate dehydrogenase | |
| Normal (%) | 32 (64) |
| Elevated (%) | 18 (36) |
| ECOG performance status | |
| 0 (%) | 23 (46) |
| 1 (%) | 22 (46) |
| 2 (%) | 2 (4)a |
| Primary site | |
| Cutaneous | |
| Torso (%) | 13 (26) |
| Head and neck (%) | 11 (22) |
| Extremity (%) | 11 (22) |
| Multiple (%) | 2 (4) |
| Unknown (%) | 4 (8) |
| Ocular (%) | 6 (12) |
| Mucosal (%) | 2 (4) |
| Soft parts (%) | 1b (2) |
a
ECOG performance status was not documented for two patients.
b
Patient with melanoma of the soft parts included in toxicity, but not response assessments.